

FDA Drug Approvals

New Generic Approvals			
Drug Name	Uses/Treatment	Pricing Information	Other Information
Fesoterodine Fumarate (Toviaz)	Treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency	Pricing information not yet available	<ul style="list-style-type: none"> Step therapy exists for this category of drugs
Imatinib Mesylate (Gleevec)	Oral specialty drug used for specific cancer treatments	Pricing information not yet available	<ul style="list-style-type: none"> Anticipated launch date is 02/01/2016 Will be rolled into MedTrak's split-fill program for certain oral anti-cancer agents Will be subject to MedTrak's PA process for specialty medications

New Brand Approvals			
Drug Name	Uses/Treatment	Pricing Information	Other Information
Basaglar	Long-acting insulin glargine for the treatment of type 1 and type 2 diabetes	Pricing information not yet available	<ul style="list-style-type: none"> Similar to Sanofi's Lantus Anticipated market entry not until December 2016 Non-formulary upon market entry
Zurampic	Treatment of hyperuricemia associated with gout	Pricing information not yet available	<ul style="list-style-type: none"> Indicated as add-on therapy only and not monotherapy Non-formulary upon market entry.

New Specialty Approvals			
Drug Name	Uses/Treatment	Pricing Information	Other Information
Alecensa	Treatment of metastatic non-small cell lung cancer (NSCLC)	Cost approximately \$14,800/month	<ul style="list-style-type: none"> Indicated to be used as 2nd line therapy for NSCLC Will be subject to MedTrak's PA process for specialty medications Non-formulary upon market entry
Bendeka	Treatment of chronic lymphocytic leukemia (CLL) & non-Hodgkin's lymphoma (NHL)	Pricing information not yet available	<ul style="list-style-type: none"> Indicated first line for CLL Indicated to be used as 2nd line for NHL Will be subject to MedTrak's PA process for specialty medications Non-formulary upon market entry

Uptravi	For the treatment of pulmonary arterial hypertension (PAH)	Pricing information not yet available	<ul style="list-style-type: none">• Other similar oral treatments already commercially available• Will be subject to MedTrak's PA process for specialty medications.• Non-formulary upon market entry
----------------	--	---------------------------------------	---